Anke Hemmerling, MD, PhD, MPH

Title(s)Associate Professor, Campuswide Accounting
Address550 16th Street, #3760
San Francisco CA 94158
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Humboldt University , Berlin, GermanyMD06/1999Medicine
    Humboldt University , Berlin, GermanyPhD08/2003Medical Sciences
    University of California, Berkeley, Berkeley, CaliforniaMPH05/2004Public Health

    Collapse Overview 
    Collapse Overview
    Anke Hemmerling, MD PhD MPH, is an Associate Adjunct Professor in the UCSF Department of Obstetrics, Gynecology and Reproductive Sciences, and the Director of the Interdisciplinary MPH Program in the UC Berkeley School of Public Health.

    She received her medical and public health training at the Humboldt University in Berlin (Germany) and at the University of California, Berkeley (UCB). During her clinical training, she repeatedly worked in health projects and hospitals in Latin America.

    Always with a focus on global women’s health, her early career research covered medication abortion, infertility and fertility choices, and safe motherhood.
    Her current clinical research is focusing on the prevention of HIV and other genital infections such as bacterial vaginosis in women, conducting a number of clinical trials in the US and South Africa. She served as the protocol co-Chair of the NIH-sponsored multi-site phase 2B study for the prevention of bacterial vaginosis using the live biotherapeutic product LACTIN-V.

    At UC San Francisco and UC Berkeley, she is mentoring and teaching several courses for medical students, undergraduate and graduate students, as well as post-doctoral students in several educational programs.

    Dr. Hemmerling serves as a senior technical adviser for the Initiative for Multipurpose Prevention Technologies for Reproductive Health (IMPT) and on several data safety monitoring boards for federally funded clinical studies. In addition, she is a member of the Education Committee at the UCGHI Center of Expertise in Women’s Health, Gender and Empowerment.

    Areas of Interest:
    • Prevention of sexually transmitted infections (STI)
    • Drug development: Microbicides and live biotherapeutic products to prevent HIV/STI
    • Fertility Choices
    • Safe Motherhood

    Collapse Research 
    Collapse Research Activities and Funding
    Sustainable Development for Improved HIV Health and Prevention in Kenya (SD4H-Kenya)
    NIH D43TW011306Apr 22, 2020 - Dec 31, 2024
    Role: Co-Investigator
    Phase 2 placebo-controlled randomized trial of LACTIN-V (Lactobacillus crispatus CTV-05) among women at high risk of HIV acquisition in Durban, South Africa
    NIH R01HD098978Jun 12, 2019 - Mar 31, 2023
    Role: Co-Investigator
    Preclinical Development of MucoCept
    NIH U01AI123082Aug 6, 2015 - Jul 31, 2018
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Vaginal fungi are associated with treatment-induced shifts in the vaginal microbiota and with a distinct genital immune profile. Microbiol Spectr. 2024 Jun 24; e0350123. Armstrong E, Hemmerling A, Miller S, Huibner S, Kulikova M, Liu R, Crawford E, Castañeda GR, Coburn B, Cohen CR, Kaul R. PMID: 38912808.
      View in: PubMed   Mentions:    Fields:    
    2. Vaginal Lactobacillus crispatus persistence following application of a live biotherapeutic product: colonization phenotypes and genital immune impact. Microbiome. 2024 Jun 21; 12(1):110. Armstrong E, Hemmerling A, Miller S, Huibner S, Kulikova M, Crawford E, Castañeda GR, Coburn B, Cohen CR, Kaul R. PMID: 38907268; PMCID: PMC11191164.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Response to Antibiotic Treatment of Bacterial Vaginosis Predicts the Effectiveness of LACTIN-V (Lactobacillus crispatus CTV-05) in the Prevention of Recurrent Disease. Sex Transm Dis. 2024 Jun 01; 51(6):437-440. Hemmerling A, Wierzbicki MR, Armstrong E, Cohen CR. PMID: 38733973; PMCID: PMC11090451.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    4. Editorial: Multipurpose prevention technologies: call for innovative strategies to address critical priorities and gaps. Front Reprod Health. 2024; 6:1417974. Soh C, van der Straten A, Hemmerling A, Turpin JA, Young Holt B. PMID: 38827819; PMCID: PMC11140149.
      View in: PubMed   Mentions:
    5. Expanding the pipeline for multipurpose prevention technologies: compounds with potential activity to prevent or treat HIV and other STIs. Sex Transm Infect. 2023 05; 99(3):203-207. Young Holt B, Hemmerling A, Moore S, Yang K. PMID: 36878691.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    6. Treatment Success Following Standard Antibiotic Treatment for Bacterial Vaginosis Is Not Associated With Pretreatment Genital Immune or Microbial Parameters. Open Forum Infect Dis. 2023 Jan; 10(1):ofad007. Armstrong E, Hemmerling A, Joag V, Huibner S, Kulikova M, Crawford E, Castañeda GR, Anzala O, Obila O, Shahabi K, Ravel J, Coburn B, Cohen CR, Kaul R. PMID: 36726539; PMCID: PMC9887266.
      View in: PubMed   Mentions: 1  
    7. Recovery and Resilience in the Canal Community: Economic Impacts and Solutions During the COVID-19 Pandemic. J Racial Ethn Health Disparities. 2023 06; 10(3):1234-1258. Bichkoff H, Huerta Niño R, Hemmerling A, Ho K, Huancas CG, Burke A, Guzman V, Allen R, Coe L, Salazar E, Wong M. PMID: 35606617; PMCID: PMC9126107.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    8. Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial. Lancet Microbe. 2022 06; 3(6):e435-e442. Armstrong E, Hemmerling A, Miller S, Burke KE, Newmann SJ, Morris SR, Reno H, Huibner S, Kulikova M, Nagelkerke N, Coburn B, Cohen CR, Kaul R. PMID: 35659905; PMCID: PMC9188188.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    9. Metronidazole treatment rapidly reduces genital inflammation through effects on bacterial vaginosis-associated bacteria rather than lactobacilli. J Clin Invest. 2022 03 15; 132(6). Armstrong E, Hemmerling A, Miller S, Burke KE, Newmann SJ, Morris SR, Reno H, Huibner S, Kulikova M, Liu R, Crawford ED, Castañeda GR, Nagelkerke N, Coburn B, Cohen CR, Kaul R. PMID: 35113809; PMCID: PMC8920324.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    10. Connecting the Dots: Translating the Vaginal Microbiome Into a Drug. J Infect Dis. 2021 06 16; 223(12 Suppl 2):S296-S306. Lagenaur LA, Hemmerling A, Chiu C, Miller S, Lee PP, Cohen CR, Parks TP. PMID: 33330916; PMCID: PMC8502429.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    11. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. Reply. N Engl J Med. 2020 08 20; 383(8):791-792. Cohen CR, Parks T, Hemmerling A. PMID: 32813960.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. Bridging the gap: advancing multipurpose prevention technologies from the lab into the hands of women†. Biol Reprod. 2020 08 04; 103(2):286-288. Young Holt B, Kiarie J, Kopf GS, Nanda K, Hemmerling A, Achilles SL. PMID: 32657337; PMCID: PMC7401373.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    13. Towards a roadmap to advance non-hormonal contraceptive multipurpose prevention technologies: strategic insights from key stakeholders†. Biol Reprod. 2020 08 04; 103(2):289-298. Hemmerling A, Christopher E, Young Holt B. PMID: 32639007; PMCID: PMC7401408.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    14. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med. 2020 05 14; 382(20):1906-1915. Cohen CR, Wierzbicki MR, French AL, Morris S, Newmann S, Reno H, Green L, Miller S, Powell J, Parks T, Hemmerling A. PMID: 32402161; PMCID: PMC7362958.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    15. Understanding Nonadherence with Hydroxychloroquine Therapy in Systemic Lupus Erythematosus. J Rheumatol. 2019 10; 46(10):1309-1315. Liu LH, Fevrier HB, Goldfien R, Hemmerling A, Herrinton LJ. PMID: 30709949.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    16. A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV. Eur J Contracept Reprod Health Care. 2018 Oct; 23(5):326-334. Young Holt B, Dellplain L, Creinin MD, Peine KJ, Romano J, Hemmerling A. PMID: 30247084.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsPHPublic Health
    17. Nutrition Education in Internal Medicine Residency Programs and Predictors of Residents' Dietary Counseling Practices. J Med Educ Curric Dev. 2018 Jan-Dec; 5:2382120518763360. Khandelwal S, Zemore SE, Hemmerling A. PMID: 29594191; PMCID: PMC5865517.
      View in: PubMed   Mentions: 24  
    18. Emerging Technologies to Prevent Pregnancy and Sexually Transmitted Infections in Women. Semin Reprod Med. 2016 May; 34(3):159-67. Seidman D, Hemmerling A, Smith-McCune K. PMID: 26956691.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Ensuring successful development and introduction of multipurpose prevention technologies through an innovative partnership approach. BJOG. 2014 Oct; 121 Suppl 5:3-8. Young Holt B, Romano J, Manning J, Hemmerling A, Shields W, Vyda L, Lusti-Narasimhan M. PMID: 25335832.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    20. Prioritizing multipurpose prevention technology development and investments using a target product profile. Antiviral Res. 2013 Dec; 100 Suppl:S32-8. Romano J, Manning J, Hemmerling A, McGrory E, Holt BY. PMID: 24188707.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    21. Developing multipurpose reproductive health technologies: an integrated strategy. AIDS Res Treat. 2013; 2013:790154. Harrison PF, Hemmerling A, Romano J, Whaley KJ, Young Holt B. PMID: 23533733; PMCID: PMC3600264.
      View in: PubMed   Mentions: 15  
    22. Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations. Sex Transm Dis. 2012 Sep; 39(9):710-2. Hemmerling A, Harrison WG, Brown JM, Moscicki B, Oziemkowska M, Bukusi EA, Cohen CR. PMID: 22902667; PMCID: PMC3726043.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    23. Effects of bacterial vaginosis-associated bacteria and sexual intercourse on vaginal colonization with the probiotic Lactobacillus crispatus CTV-05. Sex Transm Dis. 2011 Nov; 38(11):1020-7. Ngugi BM, Hemmerling A, Bukusi EA, Kikuvi G, Gikunju J, Shiboski S, Fredricks DN, Cohen CR. PMID: 21992977; PMCID: PMC3193282.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    24. Probiotics: the potential for a live microbicide to prevent HIV. J Acquir Immune Defic Syndr. 2011 Mar 01; 56(3):e98-101. Hemmerling A, Cohen CR. PMID: 21317584; PMCID: PMC4422170.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    25. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis. 2010 Dec; 37(12):745-50. Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Foster-Rosales A, Cohen CR. PMID: 20644497.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    26. Women front and center: the opportunities of involving women in participatory health research worldwide. J Womens Health (Larchmt). 2010 Nov; 19(11):2109-14. Decker M, Hemmerling A, Lankoande F. PMID: 20858061.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    27. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis. Sex Transm Dis. 2009 Sep; 36(9):564-9. Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Cohen CR. PMID: 19543144; PMCID: PMC2758081.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    28. Lime juice as a candidate microbicide? An open-label safety trial of 10% and 20% lime juice used vaginally. J Womens Health (Larchmt). 2007 Sep; 16(7):1041-51. Hemmerling A, Potts M, Walsh J, Young-Holt B, Whaley K, Stefanski DA. PMID: 17903081.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    29. The worldwide burden of postpartum haemorrhage: Policy development where inaction is lethal. Int J Gynaecol Obstet. 2006 Nov; 94 Suppl 2:S116-21. Potts M, Hemmerling A. PMID: 17161133.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    30. The safety of misoprostol. Int J Gynaecol Obstet. 2006 Nov; 94 Suppl 2:S149-S150. Hemmerling A. PMID: 29644678.
      View in: PubMed   Mentions:    Fields:    
    31. Misoprostol and declining abortion-related morbidity in Santo Domingo, Dominican Republic: a temporal association. BJOG. 2005 Sep; 112(9):1291-6. Miller S, Lehman T, Campbell M, Hemmerling A, Anderson SB, Rodriguez H, Gonzalez WV, Cordero M, Calderon V. PMID: 16101610.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    32. Emotional impact and acceptability of medical abortion with mifepristone: a German experience. J Psychosom Obstet Gynaecol. 2005 Mar; 26(1):23-31. Hemmerling A, Siedentopf F, Kentenich H. PMID: 15962719.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    33. Couples becoming parents: something special after IVF? J Psychosom Obstet Gynaecol. 2004 Jun; 25(2):99-113. Ulrich D, Gagel DE, Hemmerling A, Pastor VS, Kentenich H. PMID: 15715033.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    34. Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency. Clin Nephrol. 1996 Mar; 45(3):180-2. Haubitz M, Ehlerding G, Beigel A, Heuer U, Hemmerling AE, Thoma HA. PMID: 8706359.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsPHPublic Health
    35. Hepatitis B vaccination of immunosuppressed heart transplant recipients with the vaccine Hepa Gene 3 containing pre-S1, pre-S2, and S gene products. Clin Investig. 1994 May; 72(5):350-2. Wagner D, Wagenbreth I, Stachan-Kunstyr R, Thoma HA, Hemmerling AE, Flik J. PMID: 8086768.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsPHPublic Health
    Anke's Networks
    Concepts (144)
    Derived automatically from this person's publications.
    Co-Authors (14)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.